AngioDynamics has appointed Lynda Wallace as senior vice president of business development effective immediately. Ms Wallace will lead AngioDynamics’ business development and strategic planning activities and join the company’s executive leadership team, reporting directly to Jan Keltjens, chief executive officer for AngioDynamics.
During the past 20 years, Ms Wallace held various positions with Johnson & Johnson, most recently as worldwide vice president of the Topical Health Care franchise. Previously, she was vice president of business development for the Johnson & Johnson Medical Devices and Diagnostics sector.
Ms Wallace was also vice president of US and worldwide marketing at Cordis Endovascular, vice president of Business Development ar Cordis Corp and director of business development for Ortho Clinical Diagnostics and all Johnson & Johnson companies.
Jan Keltjens, chief executive officer of AngioDynamics, said: “Lynda Wallace brings an exceptional depth of knowledge of the medical industry to our company. Her extensive category and corporate development experience will be extremely useful as we continue to grow and pursue our strategic objectives. Her addition is an integral step in further strengthening our leadership team and I am delighted to welcome her to AngioDynamics.”
AngioDynamics is a provider of medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The company’s diverse product line includes radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.